Hunter syndrome: Difference between revisions
Jump to navigation
Jump to search
Line 29: | Line 29: | ||
==Treatment== | ==Treatment== | ||
[[Hunter syndrome medical therapy|Medical Therapy]] | [[Hunter syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hunter syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Hunter syndrome medical therapy|Medical Therapy]] | [[Hunter syndrome surgery|Surgery]] | [[Hunter syndrome primary prevention|Primary Prevention]] | [[Hunter syndrome secondary prevention|Secondary Prevention]] | [[Hunter syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hunter syndrome future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | ==Case Studies== |
Revision as of 00:48, 27 February 2013
For patient information click here
Hunter syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hunter syndrome On the Web |
American Roentgen Ray Society Images of Hunter syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Iduronate-2-sulfatase deficiency; MPS II; mucopolysaccharidosis II; iduronate sulphatase deficiency
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Hunter Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters
Template:Endocrine, nutritional and metabolic pathology